Related Experiment Video
Updated: Jul 11, 2026

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
Published on: August 14, 2019
Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issues
Mahmoud Abu-Shakra1, Joseph Press, Dan Buskila
1Rheumatic Diseases Unit, Department of Medicine, Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel. mahmoud@bgumail.bgu.ac.il
Abstract:
The influenza vaccine is highly efficacious in the general population; however there have been concerns about the safety, and immunogenecity of the vaccine in patients with SLE. Several studies have suggested that the immune response of patients with SLE to influenza vaccine is significantly lower than the general population, mainly in patients with age > or =50 years and those treated with prednisone. The vaccine is safe for patients with SLE and it does not affect the clinical manifestations of SLE including renal features, disease activity, or the requirement for steroids or cytotoxic drugs. However, the vaccine may trigger the generation of autoantibodies which is usually short term and is not associated with clinical significance.
Related Concept Videos
Vaccinations
Influenza
Hypersensitivity Reactions: Immune-Complex Reactions
Inhibitors of Viral Protein Synthesis
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
